PDCD1 and neoplasm: Seven weeks post reinoculation, none of the tumor-free mice from the combination and single-agent arms developed any signs of tumor growth, whereas tumors grew normally in the age-matched control mice (Fig. 4E), suggesting the potential establishment of immune memory by niraparib and its combination with anti-PD-1 therapy in BRCA-deficient tumors.